Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Applying the fragility index to randomized controlled trials evaluating total neoadjuvant therapy for rectal cancer.
Authors
Tyler McKechnie
McMaster University, Hamilton, ON, Canada
Tyler McKechnie , Kelly Brennan , Cagla Eskicioglu , Ameer Farooq , Sunil Patel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 32)
DOI
10.1200/JCO.2024.42.3_suppl.32
Abstract #
32
Poster Bd #
C13
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Circulating tumor DNA for predicting radiographic and pathologic response to total neoadjuvant therapy in locally advanced rectal cancer: ENSEMBLE-1.
First Author: Yoshinori Kagawa
Poster
2024 ASCO Annual Meeting
Total neoadjuvant therapy with split-course hypofraction radiotherapy combined with CAPOX and envafolimab followed by local excision for locally advanced very low rectal cancer (TRACE-LE): An open-label, single-arm, multicenter, phase II trial.
First Author: Weizhong Jiang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
International real-world study of TOTAL neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC).
First Author: Alessandro Audisio